Sor­ren­to's new pain play­er Scin­til­la go­ing so­lo af­ter $200M buy­out deal

Sor­ren­to’s new pain drug sub­sidiary Scin­til­la is spin­ning out as a so­lo op­er­a­tion af­ter the San Diego-based biotech bagged its sec­ond ac­qui­si­tion deal in a mat­ter of days, snap­ping up Sem­nur Phar­ma­ceu­ti­cals for $60 mil­lion in cash and stock and a set of mile­stones worth up to $140 mil­lion.  The lat­est deal gives Scin­til­la a back pain pro­gram on the thresh­old of Phase III along with some new pipeline boast­ing rights as it lays claim to be­com­ing a “ma­jor play­er” in the tur­bu­lent pain med­ica­tion mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER